IS4847A - Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni - Google Patents

Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni

Info

Publication number
IS4847A
IS4847A IS4847A IS4847A IS4847A IS 4847 A IS4847 A IS 4847A IS 4847 A IS4847 A IS 4847A IS 4847 A IS4847 A IS 4847A IS 4847 A IS4847 A IS 4847A
Authority
IS
Iceland
Prior art keywords
heart failure
treatment
endothelin antagonists
blooded animal
warm blooded
Prior art date
Application number
IS4847A
Other languages
English (en)
Inventor
J. Lynch Joseph
-Tang Shen You
Original Assignee
Banyu Pharmaceutical Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharmaceutical Co. Ltd. filed Critical Banyu Pharmaceutical Co. Ltd.
Publication of IS4847A publication Critical patent/IS4847A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
IS4847A 1996-04-04 1998-09-15 Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni IS4847A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1488296P 1996-04-04 1996-04-04
PCT/US1997/003737 WO1997037665A1 (en) 1996-04-04 1997-03-19 Method of treating heart failure with endothelin antagonists

Publications (1)

Publication Number Publication Date
IS4847A true IS4847A (is) 1998-09-15

Family

ID=21768326

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4847A IS4847A (is) 1996-04-04 1998-09-15 Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni

Country Status (25)

Country Link
US (3) US5834483A (is)
EP (1) EP0906108B1 (is)
JP (2) JP3345891B2 (is)
KR (1) KR20000005178A (is)
CN (1) CN1215335A (is)
AT (1) ATE297739T1 (is)
AU (1) AU723351B2 (is)
BG (1) BG102716A (is)
BR (1) BR9708525A (is)
CA (1) CA2249330C (is)
CZ (1) CZ296098A3 (is)
DE (1) DE69733557T2 (is)
EA (1) EA003587B1 (is)
EE (1) EE9800315A (is)
ES (1) ES2241047T3 (is)
HU (1) HUP9903893A3 (is)
IL (1) IL126175A (is)
IS (1) IS4847A (is)
NO (1) NO984564L (is)
NZ (1) NZ331789A (is)
PL (1) PL329077A1 (is)
SK (1) SK130098A3 (is)
TR (1) TR199801988T2 (is)
UA (1) UA50761C2 (is)
WO (1) WO1997037665A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801988T2 (xx) * 1996-04-04 2000-08-21 Banyu Pharmaceutical Co.,Ltd. Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
JPH11514676A (ja) * 1996-08-09 1999-12-14 メルク エンド カンパニー インコーポレーテッド 立体選択的脱酸素化反応
ATE259800T1 (de) 1998-01-21 2004-03-15 Banyu Pharma Co Ltd Substituierte 5-(2,2difluor-1,3-benzodioxol-5-yl) cyclopentenopyridinderivate
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2004060885A1 (ja) * 2002-12-27 2004-07-22 Kaneka Corporation 光学活性2−チオメチル−3−フェニルプロピオン酸誘導体およびその合成中間体の製造法
KR20150132601A (ko) 2003-11-17 2015-11-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
NZ549535A (en) 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
US20100040666A1 (en) 2005-06-24 2010-02-18 Hiroshi Azuma Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent
AR080683A1 (es) 2010-03-16 2012-05-02 Novartis Ag Composiciones farmaceuticas de aliskiren y metodos de administracion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
SK130595A3 (en) 1993-04-27 1996-06-05 Smithkline Beecham Corp New indane and indene derivatives, preparing method, pharmaceutical compositions containing them and their use
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
WO1995005374A1 (en) * 1993-08-18 1995-02-23 Banyu Pharmaceutical Co., Ltd. Fused heteroaromatic cyclopentene derivative having endothelin-antagonist activity
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
TR199801988T2 (xx) * 1996-04-04 2000-08-21 Banyu Pharmaceutical Co.,Ltd. Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.

Also Published As

Publication number Publication date
EE9800315A (et) 1999-06-15
ATE297739T1 (de) 2005-07-15
CA2249330C (en) 2005-08-09
EP0906108A4 (en) 2000-12-06
ES2241047T3 (es) 2005-10-16
EP0906108A1 (en) 1999-04-07
CN1215335A (zh) 1999-04-28
NO984564D0 (no) 1998-09-30
EA199800889A1 (ru) 1999-04-29
HUP9903893A3 (en) 2001-05-28
DE69733557D1 (de) 2005-07-21
HUP9903893A2 (hu) 2001-04-28
KR20000005178A (ko) 2000-01-25
SK130098A3 (en) 1999-05-07
NO984564L (no) 1998-12-04
AU2202597A (en) 1997-10-29
WO1997037665A1 (en) 1997-10-16
TR199801988T2 (xx) 2000-08-21
US6087360A (en) 2000-07-11
CA2249330A1 (en) 1997-10-16
IL126175A (en) 2003-05-29
UA50761C2 (uk) 2002-11-15
JP2002220337A (ja) 2002-08-09
IL126175A0 (en) 1999-05-09
US6380195B1 (en) 2002-04-30
EP0906108B1 (en) 2005-06-15
US5834483A (en) 1998-11-10
JP3345891B2 (ja) 2002-11-18
BR9708525A (pt) 1999-08-03
EA003587B1 (ru) 2003-06-26
PL329077A1 (en) 1999-03-15
JP2000510824A (ja) 2000-08-22
AU723351B2 (en) 2000-08-24
CZ296098A3 (cs) 1999-06-16
BG102716A (en) 1999-09-30
DE69733557T2 (de) 2005-11-03
NZ331789A (en) 2000-05-26

Similar Documents

Publication Publication Date Title
CY1110282T1 (el) Ενωσεις για την αγωγη της απωλειας βαρους
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
IL130083A0 (en) 3-Pyridyl enantiomers and their use as analgesics
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
ES2166001T3 (es) Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos.
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
NO20003313D0 (no) Terapeutiske midler
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
SE0100684D0 (sv) New subject-matter
ATE149840T1 (de) Behandlung von leberkrebs
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
MX9200755A (es) Tratamiento de carcinoma pulmonar de celulas no pequeñas.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
EA200100041A1 (ru) Способ лечения